
|Articles|April 25, 2019
Urology Times Program Director Panel
Advertisement
Urology Times is the leader in clinical analysis and perspective for practicing urologists. But now, we have more content tailored to residents than ever. Take the next step and join our Program Director Panel to help us shape content for young doctors.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
4
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
5











